Latest Breaking News On - A rare and often rapidly fatal form of cancer associated with asbestos exposure which has limited therapeutic options - Page 1 : vimarsana.com

The phase 3 clinical trial, published recently in JAMA Oncology and sponsored by Polaris Pharmaceuticals, has unveiled a breakthrough in the treatment of malignant pleural mesothelioma (MPM), a rare and often rapidly fatal form of cancer associated with asbestos exposure and which has limited therapeutic options.

Polaris pharmaceuticalsQueen mary barts cancer instituteQueen maryBarts cancer instituteProfessor szlosarekHe phase 3 clinical trialUblished recently in jama oncology and sponsored by polaris pharmaceuticalsAs unveileda breakthrough in the treatment of malignant pleural mesothelioma mpmA rare and often rapidly fatal form of cancer associated with asbestos exposure which has limited therapeutic options